{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:38:18Z","timestamp":1792791498559,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018573","name":"Sun Yat-sen University Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018573","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Guangdong Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2022A1515010490"],"award-info":[{"award-number":["2022A1515010490"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.canlet.2025.217851","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T11:20:23Z","timestamp":1748949623000},"page":"217851","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Transarterial chemoembolization combined with intra-arterial infusion of sintilimab and bevacizumab for advanced hepatocellular carcinoma: a phase 2 study"],"prefix":"10.1016","volume":"628","author":[{"given":"Mao-Yuan","family":"Mu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-Xiong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2922-7618","authenticated-orcid":false,"given":"Yu-Zhe","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Bo","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Jie","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4086-2575","authenticated-orcid":false,"given":"Fei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2025.217851_bib1","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41575-020-00395-0","article-title":"Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma","volume":"18","author":"Llovet","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.canlet.2025.217851_bib2","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.annonc.2021.02.014","article-title":"Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines","volume":"32","author":"Vogel","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2025.217851_bib3","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.canlet.2025.217851_bib4","doi-asserted-by":"crossref","first-page":"541","DOI":"10.6004\/jnccn.2021.0022","article-title":"Hepatobiliary cancers, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Benson","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.canlet.2025.217851_bib5","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","article-title":"Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study","volume":"22","author":"Ren","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2025.217851_bib6","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S1470-2045(23)00469-2","article-title":"Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial","volume":"24","author":"Llovet","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2025.217851_bib7","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","article-title":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2025.217851_bib8","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2025.217851_bib9","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1159\/000488035","article-title":"Guidelines for diagnosis and treatment of primary liver cancer in China (2017 edition)","volume":"7","author":"Zhou","year":"2018","journal-title":"Liver Cancer"},{"key":"10.1016\/j.canlet.2025.217851_bib10","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1159\/000367757","article-title":"Use of transarterial chemoembolization (TACE) and sorafenib in patients with unresectable hepatocellular carcinoma: US regional analysis of the GIDEON registry","volume":"5","author":"Geschwind","year":"2016","journal-title":"Liver Cancer"},{"key":"10.1016\/j.canlet.2025.217851_bib11","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41392-022-01235-0","article-title":"Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001)","volume":"8","author":"Zhu","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.canlet.2025.217851_bib12","doi-asserted-by":"crossref","first-page":"593","DOI":"10.3350\/cmh.2022.0391","article-title":"Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity","volume":"29","author":"Iwamoto","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"key":"10.1016\/j.canlet.2025.217851_bib13","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1136\/neurintsurg-2019-015137","article-title":"Advances in endovascular neuro-oncology: endovascular selective intra-arterial (ESIA) infusion of targeted biologic therapy for brain tumors","volume":"12","author":"Srinivasan","year":"2020","journal-title":"J Neurointerv Surg"},{"key":"10.1016\/j.canlet.2025.217851_bib14","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1136\/neurintsurg-2021-017900","article-title":"Follow-up of intra-arterial delivery of bevacizumab for treatment of butterfly glioblastoma in patient with first-in-human, real-time MRI-guided intra-arterial neurointervention","volume":"13","author":"Zawadzki","year":"2021","journal-title":"J Neurointerv Surg"},{"key":"10.1016\/j.canlet.2025.217851_bib15","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.canlet.2025.217851_bib16","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.232544","article-title":"Pharmacokinetic comparison of selective prostatic arterial and intravenous PSMA PET\/CT radioligand infusions in primary prostatic adenocarcinoma","volume":"312","author":"Kohlbrenner","year":"2024","journal-title":"Radiology"},{"key":"10.1016\/j.canlet.2025.217851_bib17","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1136\/gutjnl-2019-318934","article-title":"Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial","volume":"69","author":"Kudo","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.canlet.2025.217851_bib18","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1148\/radiol.2015150667","article-title":"TACE treatment in patients with sorafenib-treated unresectable hepatocellular carcinoma in clinical practice: final analysis of GIDEON","volume":"279","author":"Geschwind","year":"2016","journal-title":"Radiology"},{"key":"10.1016\/j.canlet.2025.217851_bib19","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1200\/JCO.22.00392","article-title":"Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: a phase III, randomized clinical trial (LAUNCH)","volume":"41","author":"Peng","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.217851_bib20","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2021-CT009","article-title":"IMbrave150: updated efficacy and safety by risk status in patients (pts) receiving atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) as first-line treatment for unresectable hepatocellular carcinoma (HCC)","volume":"81","author":"Finn","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2025.217851_bib21","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0140-6736(24)02551-0","article-title":"Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study","volume":"405","author":"Sangro","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2025.217851_bib22","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2025.217851_bib23","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S2468-1253(22)00339-9","article-title":"Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT): a single-arm, phase 2 trial","volume":"8","author":"Chiang","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.canlet.2025.217851_bib24","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.jhep.2018.11.029","article-title":"Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: the phase III STAH trial","volume":"70","author":"Park","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.canlet.2025.217851_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13111885","article-title":"Status quo and trends of intra-arterial therapy for brain tumors: a bibliometric and clinical trials analysis","volume":"13","author":"Rechberger","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.canlet.2025.217851_bib26","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1080\/17425247.2021.1856074","article-title":"Loco-regional drug delivery in oncology: current clinical applications and future translational opportunities","volume":"18","author":"Rossi","year":"2021","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.canlet.2025.217851_bib27","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.ophtha.2009.12.030","article-title":"Superselective ophthalmic artery chemotherapy as primary treatment for retinoblastoma (chemosurgery)","volume":"117","author":"Abramson","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.canlet.2025.217851_bib28","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1158\/1078-0432.CCR-24-0006","article-title":"Toripalimab plus bevacizumab as first-line treatment for advanced hepatocellular carcinoma: a prospective, multicenter, single-arm, phase II trial","volume":"30","author":"Chen","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2025.217851_bib29","doi-asserted-by":"crossref","first-page":"973","DOI":"10.2147\/JHC.S380439","article-title":"Retrospective study of the efficacy and safety of chemoembolization with drug-eluting microspheres combined with intra-arterial infusion of bevacizumab for unresectable hepatocellular carcinoma","volume":"9","author":"Ueda","year":"2022","journal-title":"J. Hepatocell. Carcinoma"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383525004185?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383525004185?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T18:08:41Z","timestamp":1752689321000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383525004185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":29,"alternative-id":["S0304383525004185"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2025.217851","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transarterial chemoembolization combined with intra-arterial infusion of sintilimab and bevacizumab for advanced hepatocellular carcinoma: a phase 2 study","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2025.217851","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"217851"}}